Source: Stem Cell Therapeutics Corp. via CNW Group
March 16, 2006
CALGARY, March 16 /PRNewswire-FirstCall/ - Stem Cell Therapeutics Corp. has reported positive results from its Phase I clinical trial in support of its lead therapeutic program for stroke, NTx(TM)-265. The trial demonstrated that, for the two drugs administered to healthy volunteers, no drug related adverse events were encountered and both drugs were detected in the cerebrospinal fluid (CSF) following intramuscular administration.
No comments:
Post a Comment